Predictive And Prognostic Value Of Hepatic Steatosis In Conversion Therapy For Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis
Received 28 March 2019
Accepted for publication 1 September 2019
Published 11 September 2019 Volume 2019:11 Pages 8315—8326
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Bilikere Dwarakanath
Mi Jian,1,* Wenju Chang,1,2,* Li Ren,1,2,* Tianyu Liu,1,* Yijiao Chen,1 Ye Wei,1,2 Qi Lin,1,2 Jianmin Xu,1,2 Xinyu Qin1,2
1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, People’s Republic of China; 2Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Zhongshan Hospital, Fudan University, Shanghai 200030, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xinyu Qin; Jianmin Xu
Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200030, People’s Republic of China
Tel +86 21 6404 1990 Ext 3449
Fax +86 21 6403 8038
Email firstname.lastname@example.org; email@example.com
Purpose: To evaluate the role of hepatic steatosis (HS) in patients with synchronous colorectal liver-limited metastases (CLLMs) undergoing conversion therapy.
Patients and methods: From March 2013 to March 2017, a total of 406 patients with initially unresectable CLLMs accepted conversion therapy in multidisciplinary team (MDT). Before the implementation of conversion therapy, all patients underwent CT scan to assess the presence of hepatic steatosis and divided into the HS group (n = 124) and the non-HS group (n = 282). After using propensity score matching (PSM) to eliminate the potential confounding bias of the two groups, the conversion hepatectomy rate and long-term oncological survival in two groups were compared.
Results: After 1:1 PSM, no significant difference was observed at baseline between patients in the HS group (n = 119) and the non-HS group (n = 119). Patients in the HS group had higher conversion hepatectomy rate from MDT evaluation (31.1% vs 18.5%, P = 0.029) and actual hepatectomy rate (30.2% vs 18.5%, P = 0.030), when compared with patients in the non-HS group, respectively. In addition, the HS group achieved better progression-free survival (PFS, P = 0.047) and overall survival (OS, P = 0.035) than that of the non-HS group. Multivariate logistic analysis confirmed that pretreatment HS was an independent predictor for conversion hepatectomy rate (OR, 2.393; 95% CI, 1.463–4.315, P = 0.001), and multivariate Cox analysis revealed that HS was an independent prognostic factor for PFS (HR, 0.493, 95% CI 0.281–0.866, P = 0.014) and OS (HR, 0.559, 95% CI 0.398–0.785, P = 0.001).
Conclusion: For CLLM patients who underwent conversion therapy, hepatic steatosis could be an effective predictor for conversion hepatectomy rate and an independent prognostic factor for PFS and OS.
Keywords: colorectal cancer, liver metastases, conversion therapy, hepatic steatosis, objective response rate, survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]